A systematic review of financial toxicity measurement instruments for cancer patients based on the COSMIN guideline

The COST is provisionally recommended for measuring financial toxicity in cancer patients. The methodological quality and measurement properties of existing financial toxicity instruments still require further improvement. Future research should adhere strictly to the COSMIN guideline to validate existing tools or develop new, high-quality instruments with comprehensive evaluations of their measurement properties.